call call. like through that joining going Laura, guide for to questions today. Also, today. everyone our clinical questions with I'd development before update the These Thank go to I'm thanks who help activities. I'll to thank and comments an on you, the start had the submitted our investors
pivotal to MASTERS-X ischemic Our continues stroke study progress.
During quarter, the and we the clinical sites into added continued study. enrollment
call, that ramped have our mentioned we for up year MASTERS-X in and production on Healios' at TREASURE production for As earnings the point. prior we earlier study the completed study
Europe have once sites by in Our end sites on the planned initiated the bring Based and other begin on of of the to most to have year, areas we board. we U.S. will intention enrolling once the U.S. favorable and and sites is other and fully international our locations. numbers early can achieve is America, enrollment Once are fully core we our have North all plan strong we sites enrollment to sites on Europe data, activated. initiated, the core of in believe study we
the XXXX. before end study Our of to been of enrollment stated the goal has complete
study. fully core have we be in our However, to better completing for once sites and and the enrollment activated we the a lines enrolling, estimate position will time
its part a in been Turning constraints announced quarter investigational completed they had initiation it second over trial progress ischemic has numbering earlier in that Japan, in all due slower the sites of advanced study than XX product in bit total. the for, to TREASURE stroke to study. in has than Japan. Healios Healios' more clinical sites hoped Healios the enrollment quarter.
Also team designation in complete as disclosures trials that under However, preliminary study the reminder, possible. it to the qualifies for some review expected is projected In for measures of to as the is public Japanese Study medicines. an our its program, the progressive for that in framework promising ARDS exploratory therapy from for regenerative expedited their MUST-ARDS program Sakigake regulatory and study. enrollment the complete enable a patients. clinical MultiStem as has we intends Healios stroke called to soon results approval January, released ischemic be pursue clinical has time Healios meaning process mid-XXXX. Healios to summary at
the designation for FDA fast-track we quarter, ARDS the from second program. the During received
for of referred ONE-BRIDGE XX in clinical from the the MUST-ARDS ongoing designed April. Healios the adding MUST-ARDS ARDS release clinical The study, be substantial patients ARDS, from eligible its trial suggests with in and MultiStem clinical ONE-BRIDGE under potential for for data, enrolled and in patients. Japan in study study. as benefit for initiated is these treatment for Healios regenerative enrolling evaluate approval a ARDS. Japan pneumonia-induced to to Data the framework that first regulatory progressive pneumonia-induced and our study patients patient the this with pneumonia-induced Following will is subjects subjects study sites with contingent
geographies. smaller size success from of arrangement could interest Japanese indication first. given process reduces possible health data the the ventilator-free mortality, and of in study ARDS caring days justified the for In may therefore, and intensive given approval available a in our TREASURE It Healios' review line and for what observed study on for patients we we study. significant from be in and the Given would believe patients, be that ARDS' that study, other this favorable Healios days ONE-BRIDGE a considerable of be MultiStem from ICU-free the well-being our impact could cost patients on MUST-ARDS with ventilator in the meaningfully is amount development taken area results this in event, in before and any unit, and license reimbursement development with through regulatory increases we the benefit treatment our care
we challenges AMI we our As study. enrolling previously, in Phase have have mentioned had substantial II
and Phase affected around designed As catheter-based the study extensive refresher, I data part to enrollment due practices following administration have a shortly potential conditions study in for to study infarct-related cells in targeted which well promising perfusion deficits. a severe of was attacks large loss with NSTEMI for types nonclinical for demonstrating as therapy MultiStem foundation patients changes the subjects in the the disease. The as been certain the heart the treat patients, for cardiovascular The with of our results heart was are challenges our area. cell treatment function
NSTEMI available identify time has cath more window subjects. and intervention accelerated to higher the the and treatment to patients, rates treatment of example, For enroll during time the meaning lab, reduced aggressive
approach Further, in care resulted intervention our clinical patients sites. the through standard severity been radial the has has to impact had based an and on access improved catheterization access in lower-than-expected coming at of sites. clinical our Additionally, femoral trend some
intended Unfortunately, a change these We've design. address the the variety impact steps design. had and to undertaken study line the issues us we of measures and that fundamentally leaving improve unless study have hoped the the low integrity for, a not long time enrollment had maintaining enrollment while we with
As a the way from enrolled of to we best to determine result, undertake the evaluation us forward. available an the subjects data help have elected
data and further information once about we've area our provide implications. strategy will in its considered the We this evaluated
operational dysfunction reducing and the complications preparations and advanced Finally, trauma around treatment submission, to now year. study, planned shortly to trauma, the adverse this finalizing for have initiation end planning We're with inflammatory start MultiStem study the we the is our which the of for the regulatory for are the designed trial the severe the with respect of objective and of evaluate toward following IND organ related events. of and clinical
front we We relevant progress areas. will and as provide on other the updates make regulatory further additional
development business Turning to front. the
critical are We particularly potential ARDS partnering evaluating care and engaged like programs involving our in opportunities, stroke, others.
the additional companies. study and interest recent generated example, MUST-ARDS leading global has from data For regional
any structure in areas, we finding for the the right but appropriate value evaluate must indications the for stakeholders and business these intend are important arrangements, this to to We commercial geographies will licenses deal for if partner geographies means focus certain success to even and focused. continue We our believe and with business ultimate get and appropriate also may partners be partnering we that that wait. the on opportunities
Healios' to opportunity trade negotiations. could In on pursuing, some disclosed to we potential cell for indications. certain expiration for and an of Uncertainty China dispute the every end, expansion. In in June, the to negotiation therapy due develop the escalating the the of may terms have had option in respect we for China rights however. with key impact China agree be the first commercialize Not worth during may MultiStem right not
has with Healios September warrant exclusive where the rights negotiation million to limited X XXXX. purchase a and result, result, a of in a respect to stock and the China, Athersys' per price shares $X.XX As premium greater its to with share now market no defined priced is expiring longer at as
we our underway we trade we not commercial partnering China China, develop in rights companies opportunity already cell develop to potential unless to the sufficiently is are discussions commercialize the company. China, which plays as evaluate of That dispute willing have size about in out. itself and opportunity therapy other continue to rights and with our out-license to the attractive the will business Given said,
development an a provide on area. research Recently, our health to update we animal have request received the and in
in opportunities the We health, the made about animal have in remain this area and space. animal particularly progress in positive companion
an potential indication. important of arrangement results health evaluations animals, a we evaluate with animal completed company, companion our cell recently therapy for The in initial demonstrate leading the significant animal Under proof to studies principle opportunity. technology and our a market to treat suggest an technology
the areas Additionally, research other to and product make on and cats focus in in with we dogs, continue a progress developing health platforms horses. animal
research the and in rights are area. our We initial commercialization about discussions other collaborator in companies animal with health development and
circumstances Given our space evaluate animal will programs, though, to on focus proceed human leading prudently warrant. and in as opportunities our health the continue we health
among controls As we a increase process are process production reduce manufacturing and manufacturing things. midst scale, product development we of in and and to initiatives of cost intended quality, the enhance have conveyed other before, number
We that over years. make the a effort expect require next and investment continue increasing and to several will preparing for commercialization progress
We be source the capabilities, for advantage competitive these a of to developed, expect company. when they're sustained
to also related to therapy with the We're and develop unique site outside requirements solutions supply proprietary the working clinical chain experts logistics. to cell
store the space, For when to is trauma, on developed securely notice In product studies. cell use by used unveiled Recently, treating the who that clinical and and enable moments' cryogenic others, treatment instance, a a dispense designed among product in be stroke, product proprietary acute by a ready-to-use, being we ready critical in an clinician the care a prototype in therapy is to ARDS off-the-shelf our us. rapid in current and settings. format system to for available hospital controlled and needs pharmacies by clinicians we our needed to product past,
our enable product pivotal supply application cell studies, Our be commercial of to prepared therapy by intention regulators. approval completion and successful is to of following effective
approach is our theme We from comes A frequently last to but is up questions that today. shareholders in addressed call, in our management. worth its revisiting capital our importance, given this it
development as capital access objective sheet programs maintain overall and healthy and our Our commercialization. to to lead to is prepare for balance we approval and a advance have possible
period. investment operational our expect move We we this as to through increase
we of collaborations, and fund done development commercialization equity effort, for from including realize our As past, our the necessary. business time, intended multiple sales, fund a At initiatives, technology variety may we have through important ways, capabilities as value activities in any typically we us in discussions add business have grants develop a and to platform opportunities to as create appropriate. to important given
to We future elements maintaining business value core activities development share will value pursue partners the continue cost while -- to opportunities creation. with for and
On the access markets, equity to in our have to us have to strategy to as tools front, necessary. place efficient capital the is equity allow
follow-on routinely For statement registration place to in we have makes to efficiently if to sense. S-X instance, move us undertake an enable activity, this
at we market. in point, ATM, and less to ATM not at-the-market put equity or to an program expensive investors. easier the the place for reach potential it makes Though, Additionally, the direct program equity, this used we provide to access have us recently
want have whereby at if also a has certain meaningful add This to agreed note important an facility the equity make an capital facility degree our with long-standing in investor conditions. stock and need maintained request a our that investor of a it is has purchases to under We position we which over of it balance or is sheet, certainty gives to us stock time. to
we couple disclosed past important to of have filings. our years, the in SEC operational from initiatives, the equity facility time Over support to used time as
important stock in activity front mindful remain level with and us. the equity-related the we consideration potential associated into However, milestones price dilutive of of impact any taking
and Some a any asked beyond stock at of There to time, price briefly would are are of address that including regulatory number I A control. many and the macroeconomic factors like influences, activities, these in among given industry factors company milestones, activity conditions, investors our about and policies, announcements fundraising company affect might changes of others. have these here. stock fluctuations, number company's investor price our
buying economic and Further, though, example, can cannot we investor's investors, cannot For selling or to communicate decisions activity and value the we control we company's the regulatory investor's in an externalities. proposition an market. control
portfolio represent directly other the be be reasons in may the as or might can of major nature. these support market Sometimes significant that equity fund short move; but and be of and that simply for pressure or selling any a or -- the hard other adjustments information. pressure relevant short fund-making company generating reallocations rumors easily externalities, can drivers news reflect taking new hedge our term independent This position are be experience it may a by know, actions of a explained there such impact information. It's or stock; often investor selling not may company also suggests it important in to and to are really
of long-term on are opportunities fluctuations our with value substantial and and price for remain operational we stock creation these us. the our achievement ahead of associated shareholders While frustrating us focused investors, for execution
in the value the to We conferences, at exposure Forbes and and investors, and increase to we publish the we other financial company and on findings proposition. efforts journals its scientific in company's company, Recently, efforts reputable podcasts scientific investment regular press. take communicate our work and words were clinical educate there research and or focused to scientific institutional business outreach retail present both to we the articles for in the public regularly programs continue our example, through opportunity, to covering and We conduct the Fortune. programs and and
and on News stories & by these media. be social following of accessed under company's All can our website Athersys on news Media
call that the been not have addressed all, update. investors way for Again, one submitted questions most, we've or another. Hopefully, questions we'd ahead our like the of in earnings if submitting to thank
additional now to We'd questions. some happy be take
